AZK is likely to break W200 billion in annual sales

Published: 2008-01-09 06:59:00

Updated: 2008-01-09 06:59:00

Boosted by increase in sales of Crestor (rosuvastatin) and Atacand as strategic items, AstraZeneca Korea saw its sales in 2007 exceed 200 billion won, up 16 percent from last year's 172.7 billion won. The combined sales of Crestor and Atacand are estimated to reach 100 billion won.

We have se...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK